BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noris M, Remuzzi G. Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology 2010;30:395-408. [DOI: 10.1016/j.semnephrol.2010.06.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Noris P, Balduini CL. Investigational drugs in thrombotic thrombocytopenic purpura. Expert Opinion on Investigational Drugs 2011;20:1087-98. [DOI: 10.1517/13543784.2011.588599] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Witasp A, Ekstrom TJ, Schalling M, Lindholm B, Stenvinkel P, Nordfors L. How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients? Nephrology Dialysis Transplantation 2014;29:972-80. [DOI: 10.1093/ndt/gfu021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
3 Ohanian M, Cable C, Halka K. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol 2011;3:45-50. [PMID: 22287856 DOI: 10.2147/CPAA.S23687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
4 Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8:622-33. [PMID: 22986360 DOI: 10.1038/nrneph.2012.195] [Cited by in Crossref: 247] [Cited by in F6Publishing: 218] [Article Influence: 24.7] [Reference Citation Analysis]
5 Patel RD, Vanikar AV, Gumber MR, Kanodia KV, Suthar KS, Patel HV, Trivedi HL. Diagnosis and management of atypical hemolytic uremic syndrome in children: single centre experience. Indian J Hematol Blood Transfus 2014;30:342-6. [PMID: 25435739 DOI: 10.1007/s12288-013-0262-3] [Reference Citation Analysis]
6 Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019;114:299-311. [PMID: 31421540 DOI: 10.1016/j.molimm.2019.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
7 Greenbaum LA. Atypical Hemolytic Uremic Syndrome. Advances in Pediatrics 2014;61:335-56. [DOI: 10.1016/j.yapd.2014.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
8 May O, Merle NS, Grunenwald A, Gnemmi V, Leon J, Payet C, Robe-Rybkine T, Paule R, Delguste F, Satchell SC, Mathieson PW, Hazzan M, Boulanger E, Dimitrov JD, Fremeaux-Bacchi V, Frimat M, Roumenina LT. Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. Front Immunol 2018;9:3008. [PMID: 30619356 DOI: 10.3389/fimmu.2018.03008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
9 Carter CE, Benador NM. Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. Pediatr Nephrol 2014;29:35-50. [PMID: 23812351 DOI: 10.1007/s00467-013-2479-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
10 Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, Levin A. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158-69. [PMID: 23727165 DOI: 10.1016/S0140-6736(13)60439-0] [Cited by in Crossref: 564] [Cited by in F6Publishing: 292] [Article Influence: 62.7] [Reference Citation Analysis]
11 Regal JF, Gilbert JS, Burwick RM. The complement system and adverse pregnancy outcomes. Mol Immunol 2015;67:56-70. [PMID: 25802092 DOI: 10.1016/j.molimm.2015.02.030] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 11.9] [Reference Citation Analysis]
12 Verhave JC, Wetzels JF, van de Kar NC. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol Dial Transplant 2014;29 Suppl 4:iv131-41. [PMID: 25165180 DOI: 10.1093/ndt/gfu235] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
13 Lee EJ, Lee AI. Thrombocytopenia. Prim Care 2016;43:543-57. [PMID: 27866576 DOI: 10.1016/j.pop.2016.07.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
14 Tsai H. A Mechanistic Approach to the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome. Transfusion Medicine Reviews 2014;28:187-97. [DOI: 10.1016/j.tmrv.2014.08.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
15 Peyvandi F, Rossio R, Ferrari B, Lotta LA, Pontiggia S, Ghiringhelli Borsa N, Pizzuti M, Donadelli R, Piras R, Cugno M, Noris M. Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes. J Thromb Haemost 2016;14:340-5. [PMID: 26613809 DOI: 10.1111/jth.13210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 2011;3:5-12. [PMID: 22287852 DOI: 10.2147/CPAA.S17904] [Cited by in Crossref: 7] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
17 Nadasdy T. Thrombotic microangiopathy in renal allografts: the diagnostic challenge. Curr Opin Organ Transplant. 2014;19:283-292. [PMID: 24811438 DOI: 10.1097/mot.0000000000000074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
18 Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017;31:213-23. [PMID: 28215731 DOI: 10.1016/j.blre.2017.02.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
19 Michaux K, Bacchetta J, Javouhey E, Cochat P, Frémaux-Bacchi V, Sellier-Leclerc AL. Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatr Nephrol 2014;29:2415-9. [PMID: 25149852 DOI: 10.1007/s00467-014-2933-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
20 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Saab KR, Elhadad S, Copertino D, Laurence J. Thrombotic Microangiopathy in the Setting of HIV Infection: A Case Report and Review of the Differential Diagnosis and Therapy. AIDS Patient Care STDS 2016;30:359-64. [PMID: 27509235 DOI: 10.1089/apc.2016.0124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
22 Moatti-cohen M, Garrec C, Wolf M, Boisseau P, Galicier L, Azoulay E, Stepanian A, Delmas Y, Rondeau E, Bezieau S, Coppo P, Veyradier A. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012;119:5888-97. [DOI: 10.1182/blood-2012-02-408914] [Cited by in Crossref: 144] [Cited by in F6Publishing: 114] [Article Influence: 14.4] [Reference Citation Analysis]